Farmas USA

Los futuros se han relajado mucho. El S&P -0,15%. Aunque a partir de las 19:30, que habla un miembro de la FED veremos que camino toma esto.
IBB, a ver si hay suerte cierra el gap y se da la vuelta.

KERX
Keryx Biopharmaceuticals (KERX) announced it will webcast management presentations at the following investor conference:
A fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 13, 2016 at 12:20 p.m. Eastern Time.
Live audio webcasts of the presentations will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. Archived versions of the webcasts will be available for at least 15 days following the conclusion of the live presentation.

Un curso recomendable y gratuito para profanos que empieza ya.

Design and Interpretation of Clinical Trials

https://www.coursera.org/learn/clinical-trials?recoOrder=31&utm_medium=email&utm_source=recommendations&utm_campaign=recommendationsEmail%7Erecs_email_2016_09_11_17%3A58

CLSN

Para los que aún llevamos el cadáver, esto tiene bastante buena pinta.

Celsion Corporation Announces Independent NIH Analysis Showing Treatment with ThermoDox® Plus RFA May Significantly Improve Overall Survival of Patients with Primary Liver Cancer

The NIH analysis, which sought to evaluate the correlation between RFA burn time per tumor volume (min/ml) and clinical outcome in patients treated with ThermoDox, concluded that increased burn time per tumor volume substantially improved survival in patients with solitary lesions treated with RFA + ThermoDox® compared to patients treated with RFA alone. These findings are consistent with Celsion's analysis of the HEAT Study data showing that in patients treated with RFA for more than 45 minutes, standardized RFA plus ThermoDox resulted in a statistically significant improvement in overall survival (OS) compared to standardized RFA alone.

...latest 285 patient subgroup OS readout from the HEAT Study reported that over a 3.5 year period, there was a consistent two-year survival benefit for patients with primary liver cancer - one of the most prevalent and most deadly types of cancer in the world - who were treated with ThermoDox plus optimized RFA over the optimized RFA-only group."

NIH findings will be presented to the scientific community at the 2016 RSNA Annual Meeting: Monday, November 28, 2016, 1:00 pm to 6:00 pm

http://investor.celsion.com/releaseDetail.cfm?ReleaseID=988665

TSRO

Receives FDA Fast Track Designation For Niraparib, Initiates Rolling NDA Submission

How Congress Can Make Drug Pricing More Rational

The way this system is designed, it’s inevitable that there would be a growing disconnect between the publicized “list” price of a drug, and the real price that’s paid by large purchasers. The political class is using these anecdotes of excessive list pricing to further a legislative push for enactment of drug price controls. But the list prices that are being objectified are disconnected from the real costs, despite the best attempts of drug industry critics to blur these economic distinctions.

http://www.forbes.com/sites/scottgottlieb/2016/09/12/how-congress-can-make-drug-pricing-more-rational/#7eb4361a2f6b

"In the U.S., common causes of viral pneumonia are influenza and respiratory syncytial virus (RSV)"

http://www.cnbc.com/2016/09/12/clintons-pneumonia-just-how-bad-is-it.html

La verdad es que empiezo a ver "fantasmas" por todas partes, tanto pumpeo, directo e indirecto da miedo. Bueno, espero que tan solo sea yo.

NVAX

achn
carnada para osos